TP53 and neoplasm: Additionally, molecular alterations emerging upon tumor progression after trastuzumab treatment have been observed in several candidate genes such as TP53 (92%), EGFR (13%), cell-cycle mediators, i.e. cyclin-dependent kinases (42%) and in the PI3K/AKT/mTOR axis (21%) [103].